FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2924733306> ?p ?o ?g. }

• W2924733306 abstract "Rifapentine is a rifamycin used to treat tuberculosis. As is the case for rifampin, plasma exposures of rifapentine are associated with the treatment response. While concomitant food intake and HIV infection explain part of the pharmacokinetic variability associated with rifapentine, few studies have evaluated the contribution of genetic polymorphisms. We evaluated the effects of functionally significant polymorphisms of the genes encoding OATP1B1, the pregnane X receptor (PXR), constitutive androstane (CAR), and arylacetamide deacetylase (AADAC) on rifapentine exposure. Two studies evaluating novel regimens among southern African patients with drug-susceptible pulmonary tuberculosis were included in this analysis. In the RIFAQUIN study, rifapentine was administered in the continuation phase of antituberculosis treatment in 1,200-mg-once-weekly or 900-mg-twice-weekly doses. In the Daily RPE study, 450 or 600 mg was given daily during the intensive phase of treatment. Nonlinear mixed-effects modeling was used to describe the pharmacokinetics of rifapentine and to identify significant covariates. A total of 1,144 drug concentration measurements from 326 patients were included in the analysis. Pharmacogenetic information was available for 162 patients. A one-compartment model with first-order elimination and transit compartment absorption described the data well. In a typical patient (body weight, 56 kg; fat-free mass, 45 kg), the values of clearance and volume of distribution were 1.33 liters/h and 25 liters, respectively. Patients carrying the AA variant (65.4%) of AADAC rs1803155 were found to have a 10.4% lower clearance. HIV-infected patients had a 21.9% lower bioavailability. Once-weekly doses of 1,200 mg were associated with a reduced clearance (13.2%) compared to that achieved with more frequently administered doses. Bioavailability was 23.3% lower among patients participating in the Daily RPE study than in those participating in the RIFAQUIN study. This is the first study to report the effect of AADAC rs1803155AA on rifapentine clearance. The observed increase in exposure is modest and unlikely to be of clinical relevance. The difference in bioavailability between the two studies is probably related to the differences in food intake concomitant with the dose. HIV-coinfected patients had lower rifapentine exposures." @default.
• W2924733306 created "2019-04-01" @default.
• W2924733306 creator A5000612367 @default.
• W2924733306 creator A5003891827 @default.
• W2924733306 creator A5012638474 @default.
• W2924733306 creator A5025069184 @default.
• W2924733306 creator A5028325527 @default.
• W2924733306 creator A5033643317 @default.
• W2924733306 creator A5034898456 @default.
• W2924733306 creator A5037090118 @default.
• W2924733306 creator A5049421387 @default.
• W2924733306 creator A5053945845 @default.
• W2924733306 creator A5055539364 @default.
• W2924733306 creator A5056892721 @default.
• W2924733306 creator A5066429649 @default.
• W2924733306 creator A5070569717 @default.
• W2924733306 creator A5073732547 @default.
• W2924733306 creator A5075795989 @default.
• W2924733306 date "2019-04-01" @default.
• W2924733306 modified "2023-10-17" @default.
• W2924733306 title "A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine" @default.
• W2924733306 cites W1968940867 @default.
• W2924733306 cites W1969922063 @default.
• W2924733306 cites W1986157879 @default.
• W2924733306 cites W1989525615 @default.
• W2924733306 cites W2006583270 @default.
• W2924733306 cites W2011120498 @default.
• W2924733306 cites W2011163792 @default.
• W2924733306 cites W2029402050 @default.
• W2924733306 cites W2042763169 @default.
• W2924733306 cites W2048520788 @default.
• W2924733306 cites W2052223857 @default.
• W2924733306 cites W2061790725 @default.
• W2924733306 cites W2072475014 @default.
• W2924733306 cites W2089663335 @default.
• W2924733306 cites W2096015848 @default.
• W2924733306 cites W2098049342 @default.
• W2924733306 cites W2105096884 @default.
• W2924733306 cites W2111276287 @default.
• W2924733306 cites W2113776964 @default.
• W2924733306 cites W2117466548 @default.
• W2924733306 cites W2120416054 @default.
• W2924733306 cites W2130673871 @default.
• W2924733306 cites W2132389528 @default.
• W2924733306 cites W2139687934 @default.
• W2924733306 cites W2145156925 @default.
• W2924733306 cites W2149849113 @default.
• W2924733306 cites W2159717558 @default.
• W2924733306 cites W2307433189 @default.
• W2924733306 cites W2405710268 @default.
• W2924733306 cites W2422352973 @default.
• W2924733306 cites W2531087123 @default.
• W2924733306 cites W2582762749 @default.
• W2924733306 cites W2610453835 @default.
• W2924733306 cites W2475221066 @default.
• W2924733306 doi "https://doi.org/10.1128/aac.01964-18" @default.
• W2924733306 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6437540" @default.
• W2924733306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30670438" @default.
• W2924733306 hasPublicationYear "2019" @default.
• W2924733306 type Work @default.
• W2924733306 sameAs 2924733306 @default.
• W2924733306 citedByCount "13" @default.
• W2924733306 countsByYear W29247333062020 @default.
• W2924733306 countsByYear W29247333062021 @default.
• W2924733306 countsByYear W29247333062022 @default.
• W2924733306 countsByYear W29247333062023 @default.
• W2924733306 crossrefType "journal-article" @default.
• W2924733306 hasAuthorship W2924733306A5000612367 @default.
• W2924733306 hasAuthorship W2924733306A5003891827 @default.
• W2924733306 hasAuthorship W2924733306A5012638474 @default.
• W2924733306 hasAuthorship W2924733306A5025069184 @default.
• W2924733306 hasAuthorship W2924733306A5028325527 @default.
• W2924733306 hasAuthorship W2924733306A5033643317 @default.
• W2924733306 hasAuthorship W2924733306A5034898456 @default.
• W2924733306 hasAuthorship W2924733306A5037090118 @default.
• W2924733306 hasAuthorship W2924733306A5049421387 @default.
• W2924733306 hasAuthorship W2924733306A5053945845 @default.
• W2924733306 hasAuthorship W2924733306A5055539364 @default.
• W2924733306 hasAuthorship W2924733306A5056892721 @default.
• W2924733306 hasAuthorship W2924733306A5066429649 @default.
• W2924733306 hasAuthorship W2924733306A5070569717 @default.
• W2924733306 hasAuthorship W2924733306A5073732547 @default.
• W2924733306 hasAuthorship W2924733306A5075795989 @default.
• W2924733306 hasBestOaLocation W29247333061 @default.
• W2924733306 hasConcept C112705442 @default.
• W2924733306 hasConcept C126322002 @default.
• W2924733306 hasConcept C142724271 @default.
• W2924733306 hasConcept C181389837 @default.
• W2924733306 hasConcept C2776306059 @default.
• W2924733306 hasConcept C2776409635 @default.
• W2924733306 hasConcept C2776962512 @default.
• W2924733306 hasConcept C2776991065 @default.
• W2924733306 hasConcept C2777975735 @default.
• W2924733306 hasConcept C2779384505 @default.
• W2924733306 hasConcept C2779806340 @default.
• W2924733306 hasConcept C2780867798 @default.
• W2924733306 hasConcept C2781069245 @default.
• W2924733306 hasConcept C2908647359 @default.
• W2924733306 hasConcept C501593827 @default.
• W2924733306 hasConcept C71924100 @default.

• next